IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells.

This observation might be consistent with the results that mice from nt-KO CD19-CAR-T cell–injected groups showed a trend of faster tumor cell clearance, although with no significant difference compared with mice from ITK-KO CD19-CAR-T cell–injected groups ( Supplemental Figure 5F ).

also in 53,322 other papers